Welcome to our dedicated page for Monogram Orthopaedics SEC filings (Ticker: MGRM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sorting through Monogram Orthopaedics� SEC reports can feel like decoding a clinical trial protocol. The company’s 10-K details years of R&D for its AI-guided robotic arms and 3D-printed implants, while every 8-K may announce pivotal FDA milestones. If you need Monogram Orthopaedics insider trading Form 4 transactions before the market reacts, or want the cash-burn figures buried in the latest Monogram Orthopaedics quarterly earnings report 10-Q filing, traditional search just isn’t fast enough.
Stock Titan’s platform solves that bottleneck. Our AI instantly turns dense disclosures into plain language—a true advantage when understanding Monogram Orthopaedics SEC documents with AI. Receive real-time alerts the moment a Monogram Orthopaedics Form 4 insider transactions update posts to EDGAR, scan side-by-side comparisons of consecutive 10-Qs for shifting R&D spend, and see key risks from the Monogram Orthopaedics annual report 10-K simplified in one click. We also tag each 8-K so you can read Monogram Orthopaedics 8-K material events explained—from trial enrollment pauses to strategic distributor agreements—without technical jargon.
Whether you’re gauging surgeon adoption rates, tracking Monogram Orthopaedics executive stock transactions Form 4, or dissecting the Monogram Orthopaedics proxy statement executive compensation tables, our coverage helps you act quickly. Use AI-powered summaries to monitor segment revenue tied to robotics, set alerts for cash runway thresholds, or benchmark insider buying patterns against peers. With comprehensive, real-time access to every filing type—including earnings releases, S-1 amendments, and clinical study exhibits—Stock Titan turns Monogram Orthopaedics SEC filings into decision-ready intelligence.
Monogram Technologies, Inc. (MGRM) Quarterly Report highlights merger-related arrangements, equity financings and preferred-stock activity through June 30, 2025. The Merger consideration for Common Stock holders includes $4.04 per share in cash plus a contingent value right; Series D and E preferred holders would receive $2.25 and $100.00 per share respectively. The Company had 4,187,569 shares and the other class had 36,088,725 shares outstanding at June 30, 2025. Under a Purchase Agreement the Company may sell up to $20.0 million of Common Stock to BRPC II and had raised approximately $961,245 from 292,726 shares as of June 30, 2025. Under an At-The-Market program the Company may sell up to $25.0 million and had sold 2,454,318 shares for gross proceeds of $6.2 million. Pro-Dex exercised warrants on June 30, 2025 providing $900,000 in proceeds. The Series D Preferred underwent a Mandatory Conversion effective July 14, 2025 and no Series D shares were outstanding as of the report date. The Company disclosed a $4.0 million Termination Payment allocation under a separate agreement, including cash and Series E Preferred shares.
Monogram Technologies has entered into a merger agreement with Zimmer Biomet under which Monogram would become a wholly owned subsidiary of Zimmer Biomet if stockholders approve the transaction. Each share of Monogram common stock would receive $4.04 in cash plus one non-tradeable contingent value right (CVR) that can pay up to $12.37 in additional cash if specified milestones are met, for a maximum potential per-share consideration of $16.41.
The CVR ties payments to clinical, regulatory and commercial milestones including a proof-of-concept demo in early 2026, FDA 510(k) clearance for the fully autonomous system, and revenue targets of $156M in 2028, $381M in 2029 and $609M in 2030. The Board unanimously recommends the merger. The transaction is subject to customary closing conditions including antitrust clearance, and Zimmer Biomet represents it has sufficient funds; a delayed-draw loan of up to $15M is available to Monogram if the merger does not close. A potential $11M termination fee is also disclosed.
Monogram Technologies Inc. (MGRM) filed an 8-K on 30 Jul 2025 under Item 7.01 to furnish an email sent to shareholders.
The email directs investors to the FAQ section on the company’s Investor Relations website that addresses the previously announced Zimmer Biomet Holdings, Inc. acquisition (14 Jul 2025). No new financial statements, valuation metrics, or amended deal terms are included. The communication is provided as Exhibit 99.1 and, consistent with Reg FD, is treated as “furnished,� not “filed,� limiting Exchange Act liability.
Item 9.01 lists (i) Exhibit 99.1—Shareholder Email and (ii) the Inline XBRL cover file. No other reportable events were disclosed.
Monogram Technologies Inc. (Nasdaq: MGRM) filed a Form 8-K (Item 7.01 Regulation FD) to furnish a press release dated 29 July 2025 announcing completion of the world’s first fully autonomous, saw-based robotic total knee replacement. The surgery used Monogram’s proprietary mBōs� TKA System and was performed at Krishna Shalby Hospital in Ahmedabad, India.
The company positions the procedure as proof-of-concept for closed-loop robotic orthopedic surgery, potentially accelerating its commercialization roadmap and strategic partnerships. No financial results, guidance, or transactions were disclosed; the press release is provided as Exhibit 99.1 and is deemed “furnished,� not “filed,� limiting liability under the Exchange Act.
Forward-looking-statement language flags risks around capital needs, regulatory approvals, partner dependence and litigation. Other 8-K items (7.01, 9.01) contain only exhibit references; no pro-forma financials or statements accompany the filing.
Monogram Technologies Inc. (Nasdaq: MGRM) filed an 8-K on 28-Jul-2025 under Item 7.01 to furnish shareholder FAQs related to its previously announced acquisition by Zimmer Biomet Holdings, Inc. (announced 14-Jul-2025). The filing labels the material as soliciting under Rule 14a-12, signalling its use in the forthcoming proxy process. Exhibit 99.1 contains the full FAQ document and is incorporated by reference.
The information is being “furnished� rather than “filed,� so it is not subject to Section 18 liability and will not be automatically incorporated into other SEC filings. No additional financial terms, valuation, or closing timeline are provided. The company reiterates its emerging-growth company status and maintains Nasdaq listing under the ticker MGRM.
Zimmer Biomet Holdings, Inc. has agreed to acquire Monogram Technologies Inc. (Nasdaq: MGRM) via a cash-and-CVR merger valued at $4.04 per common share plus a contingent value right (CVR). Honey Badger Merger Sub, a wholly-owned Zimmer subsidiary, will merge with Monogram, making Monogram a wholly-owned subsidiary and prompting a post-closing Nasdaq delisting.
Key economic terms
- Common stockholders: cash consideration of $4.04 per share plus one CVR.
- Series D preferred: $2.25 cash per share.
- Series E preferred: $100.00 cash per share.
- Equity awards: in-the-money options receive the cash spread and a CVR; out-of-the-money options convert solely into a CVR.
CVR structure � up to $12.37 per CVR payable in five milestones:
- $1.04 upon proof-of-concept demo of Monogram’s partial-knee robotic system (deadline: later of 31 Jan 2026 or 30 days post-close).
- $1.08 upon FDA 510(k) clearance for fully autonomous robotic system using Zimmer implants (deadline: 31 Dec 2027).
- $3.41 if 2028 gross revenue � $156 million.
- $3.41 if 2029 gross revenue � $381 million.
- $3.43 if 2030 gross revenue � $609 million.
Closing conditions
- Majority stockholder approval.
- HSR waiting-period expiration.
- No legal restraints and no Material Adverse Effect on Monogram.
- No financing contingency.
Deal protections & ancillary agreements
- No-shop with fiduciary-out for “Superior Offer.�
- Company termination fee: $11 million.
- Voting Agreement: key holders commit to vote for the merger.
- Loan Agreement: Zimmer can provide Monogram up to $15 million in delayed-draw loans if the merger has not closed between 1 Dec 2025 and the End Date (11 Jan 2026, extendable to 11 Apr 2026); maturity 1 Dec 2027.
Timeline & next steps
- Proxy statement to be filed; shareholders to vote.
- Outside date: 11 Jan 2026 (extendable).
- Upon closing, Monogram securities will be deregistered.
This Form 8-K (filed as additional proxy soliciting material) outlines a definitive, cash-backed acquisition with long-dated revenue-based CVRs that transfer post-closing performance risk to selling shareholders.
FAQ
What is the current stock price of Monogram Orthopaedics (MGRM)?
What is the market cap of Monogram Orthopaedics (MGRM)?
